StockNews.AISignal intelligence
Alkermes plc · NASDAQ · Healthcare
Browse public ALKS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Alkermes' LUMRYZ drug proved effective in the REVITALYZ study, prompting plans for a supplemental FDA application. The stock recent surge and analyst upgrades suggest continued positive sentiment and potential growth ahead, making it a focus for investors.
View signal analysisAlkermes exceeded Q1 earnings projections with a loss of 40 cents per share and strong sales of nearly $393 million, leading to a raise in FY2026 EPS guidance. Despite a 2.6% drop in stock price post-announcement, analysts have increased price targets, indicating ongoing investor confidence.
View signal analysisAlkermes Plc (ALKS) has been flagged as overbought according to BZ Edge Rankings, signaling potential caution for momentum investors. The company may face pressure if valuation doesn’t align with performance, impacting future stock movements.
View signal analysisAlkermes sweetened bid to buy Avadel, valuing it up to $2.37 billion. Alkermes beat rival bidder Lundbeck with the higher offer.
View signal analysisLundbeck proposed $23 per share for Avadel Pharmaceuticals. Avadel's board considers Lundbeck's offer could result in a superior proposal. Alkermes agreed to acquire Avadel for $20 per share previously. Avadel shares surged 20.22% following news, reaching a 52-week high.
View signal analysisAlkermes is reviewing options following Avadel's unsolicited takeover bid. Potential impacts on ALKS depend on strategic responses to M&A activity.
View signal analysis